Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAL101
- Development stage
- Unknown
- Lead developer
- Calluna Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CAL101 is a first-in-class monoclonal antibody developed by Calluna Pharma. It targets the S100A4 protein, a damage-associated molecular pattern (DAMP) protein. S100A4 is activated during tissue stress or injury and plays a crucial role in the pathological activation and proliferation of fibroblasts and the pro-fibrotic immune response, which contribute to inflammation and scar tissue formation. By neutralizing S100A4, CAL101 aims to suppress inflammatory and fibrotic signaling pathways and restore tissue homeostasis. It is currently under investigation for the treatment of various fibrotic and fibro-inflammatory diseases, including idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and chronic plaque psoriasis.
- Brand names
- Zydelig
02
Targets
S100A4 (Ferroptosis suppressor protein 1)
Beyond the preview
Go deeper on CAL101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAL101.